The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate that whether the AML (acute myeloid leukemia)-CAMS
(Chinese Academy of Medical Sciences)-2016 regimen, includes risk-stratified therapy and the
use of Dasatinib in CBF (Core binding factor)-AML, can improve the outcome in childhood AML.